Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Interactive and Accessible Sign Language Translation - AccessibleTranslation (AT)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Türkiye
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-08-01
End date: 2020-01-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Deafness and hearing impairment are conditions in which an individual has very little or no hearing or the inability to hear as well as someone with normal hearing. It is estimated that over 5% of the global population , suffers from disabling hearing impairment. Moreover, nearly 15% of the global adult population is affected by some degree of hearing loss. Majority of which is found in the less developed nations. The most used way of communication is the sign language that comes in many forms, there are over +200 sign languages (ASL, BSL, FSL, etc.) in use around the world today, three categories of sign languages: 1) Deaf sign languages – the main language of deaf communities; 2) Auxiliary sign languages; 3) Signed modes of oral languages (known as manually coded languages). Another way of communication is to use an interpreter (Or remote VRS interpreter) to communicate with a hearing person, whichis not instantaneous as you have to book the service online or you have to hire one. Our innovative solution: AccessibleTranslation aims to permanently solve the communication problem of deaf and hearing-impaired people in their daily life. They will be able to handle their work without the need of an interpreter, a sign language speaker or trained staff in sign language. Our platform provides a real-time captioning, it captures and translates sign language into audio, it also transforms audio into sign languages, and it also translates text into sign language. It can be easily integrated in different platforms. We now aim to introduce our patent-pending solution to the assistive technologies market across Europe as initial target market and worldwide seeing how our solution offers significant communication performance and improvements and is market disrupting in its potential (Ref. Expressions of Intent in Section 4.1.2). Our new prototype designed and built is currently at TRL6 stage.

Keywords: accessible translation,sign language,deafness,hearing impairment
A New Drug Therapy for the treatment of ST Elevated Myocardial Infarction (CardioProtectMI)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Denmark
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-11-01
End date: 2020-02-29
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year in Europe alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial Infarction (MI). In the most severe cases this has a mortality rate between 6% and 14%. Clinical guidelines recommend immediate restoration of the blood flow via reperfusion therapy. However, this procedure results in high acute mortality (10%) and a significant incidence of congestive heart failure (12%) due to inflammation and ensuing cell death of the myocardial tissues. Current treatments do not provide a cardio-protective effect to mitigate this. Several potential therapies have emerged as promising cardio-protective therapeutic strategies for severe cases of MI, but up to date these have all failed to prove efficacy in later stages of human clinical trials. ResoTher Pharma ApS is a biotechnology company focused on developing a new class of therapeutics targeting the resolution of inflammatory responses. The company´s first drug candidate is a novel peptide with unique cardio-protective capabilities. Results from animal models reveal promising tissue-protective effects - decreases in myocardial damage related to the reperfusion injury (52%) and an overall improvement of the survival rate after an MI (up to 400%). The clinical validation of the lead drug will be key to demonstrate safety and efficacy in humans and allow ResoTher to establish itself in the chronic inflammatory disease market. The present SMEi Phase 1 will be of utmost importance to engage key stakeholders and prepare the clinical development plan in readiness for implementation during the Innovation Project. The clinical validation of the lead drug will lead to a significant business opportunity for ResoTher, supporting the company´s medium term strategic positioning as a unique provider of a new generation of anti-inflammatory drugs.

Keywords: myocardial infarct,cardioprotective drugs,immunomodulators
Enabling Live-Cell 4D Super-Resolution Microscopy Guided by Artificial Intelligence (SelfDriving4DSR)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Condensed matter physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Portugal
Call: ERC CONSOLIDATOR GRANTS (ERC-2020-COG, 2020)
Start date: 2021-07-01
End date: 2026-06-30
Duration (months): 60.0
Total project cost (EUR): 1999905.0
EU funding (EUR): 1999905.0
Participants: 1
Project status: SIGNED

Most fundamental biomedical discoveries are carried by indirect observation, due to our inability to follow molecular-level cellular processes non-invasively in living samples. There is a major need to develop the capacity to directly observe the molecular basis of cell regulation at relevant spatial and temporal scales. My work has focused on establishing Next-Generation Super-Resolution Microscopy able to accurately describe the nanoscale structure of living-cells, beyond the capacity of conventional imaging. Despite significant advancements, Super-Resolution Microscopy does not allow observations for more than a few minutes before damaging high-intensity illumination compromises cell behaviour. Better fluorophores and optics can partly address this problem; however, a fundamental limitation remains - humans drive imaging. In microscopy, researchers take educated guesses on how to observe a sample based on empirical criteria. Acquisition settings are then kept static, despite the diversity of spatiotemporal scales associated with cell behaviour in health and disease. This project will solve these challenges by establishing self-driving microscopes, able to adapt in real-time to the biological phenomenon under observation. Doing so, I will enable the capacity for unprecedented 4D imaging data optimised for content, resolution and quality while remaining non-invasive for long periods of time. To this end, I will bridge and evolve cutting-edge concepts in Computational Optical Microscopy and Machine Learning, effectively establishing Machine Learning Guided 4D Super-Resolution Microscopy. These approaches will enable 4D live-cell nanoscopic imaging over record periods and challenge the assumption that microscopy needs to obey homogeneous temporal sampling. Its enabling capacity will be demonstrated by visualising nanoscale cellular events previously unseen over hours, such as the molecular-level progression of viral infection.

Keywords: super resolution microscopy,optical development,machine learning,quantitative imaging,biological physics,viral infection,host pathogen interactions
Effects of permafrost thaw on the global nitrogen cycle: the role of thermokarst systems (NITROKARST)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Austria
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-02-01
End date: 2024-01-31
Duration (months): 24.0
Total project cost (EUR): 174167.04
EU funding (EUR): 174167.04
Participants: 1
Project status: CLOSED

Global change leads modifications in climate on Arctic regions, where temperatures have risen faster than in any other region on Earth. Those regions store vast amounts of soil organic matter (SOM) in permafrost soils, covering ~25% of terrestrial surface. When they thaw, it leads to rapid release of nutrients and greenhouse gases (GHG). So far, many studies have addressed the importance of permafrost thaw in the carbon cycle. However, little attention has been paid to the nitrogen (N) cycle, despite nitrous oxide (N2O) is a powerful GHG, an ozone-depleting agent and may create an unaccounted permafrost-climate feedback. Permafrost with low ice content suffers a gradual top-down thawing process during seasonal freeze-thaw period. However, thaw of ice-rich permafrost results in thermokarst processes, which occur abruptly and lead to ground surface collapse. Its widespread occurrence affects large areas (~40% of the northern permafrost region) contributing to develop ecosystems like ponds and lakes. In such ecosystems, the presence of anaerobic environments enhances microbial activity. As Arctic warms, permafrost thaw and thermokarst processes will increase, releasing soluble N into the environment and enhancing microbial decomposition of SOM. Hence, mineralization, nitrification and denitrification rates are expected to increase, and thus, N2O emissions to the atmosphere. Unfortunately, the impact of permafrost thaw on N cycling remains understudied, and almost unknown in thermokarst systems. NITROKARST will explore the underlying mechanisms of the N cycle in thermokarst systems, looking at how microbial pathways promote N transformation and how thawing controls the operation of these processes. N cycling will be studied along a thermokarst transect by combining isotope tracing, metagenomics and microcosm incubations. This multidisciplinary approach will increase our knowledge about the importance of thermokarst-affected permafrost soils in the global N cycle.

Keywords: nitrogen cycle,nitrous oxide,permafrost thaw,thermokarst,microbial metabolism,metagenomics
The Mind's Eye: Decoding Colour Experience (COLOURCODE)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: The Human Mind and Its Complexity
Panel description: Cognitive science, psychology, linguistics, theoretical philosophy
Countries involved: United Kingdom
Call: ERC STARTING GRANTS (ERC-2020-STG, 2020)
Start date: 2020-12-01
End date: 2025-11-30
Duration (months): 60.0
Total project cost (EUR): 1492132.0
EU funding (EUR): 1492132.0
Participants: 1
Project status: SIGNED

The most extraordinary products of the human mind are personal, subjective experiences such as the qualitative experience of the redness of red, yet the question of what process or processes in the brain give rise to conscious experiences remains one of the greatest scientific mysteries. The COLOURCODE project will use colour as a model system to tackle important questions necessary to approach an answer. First, COLOURCODE aims to elucidate the representation of colour in the human brain that underlies how colours appear and are experienced. Second, it aims to provide the first investigation of how the precise timing of rhythmic neural activity represents colour and drives colour perception and experience. Third, by measuring how individuals perceive colour differently from one another, the project aims to determine how colour experience is constrained by the number and type of sensors in the eye and information received from the external world. COLOURCODE will use an innovative combination of psychophysics and individual differences, along with a diverse suite of neuroscience methods including electroencephalography (EEG), steady state visually evoked potentials, functional magnetic resonance imaging (fMRI) and transcranial magnetic stimulation (TMS). COLOURCODE will provide the most detailed characterisation yet of how a stimulus attribute is represented by the human brain, driving a greater understanding of representation in neuroscience. Determining for the first time the encoding capacity of rhythmic brain activity will cause a paradigm shift in vision science as it is not part of existing theoretical models. COLOURCODE’s theoretical advances and methodological innovations will lead us closer to answering one of the most formidable questions in science and philosophy - the question of what processes give rise to conscious perceptual experiences.

Keywords: colour,representation,individual differences,ssvep,neural oscillations
ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS (UNITE4TB)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: South Africa,Germany,Germany,Italy,Spain,Germany,Germany,Germany,Germany,Ireland,Switzerland,Switzerland,Belgium,Sweden,Belgium,France,Netherlands,United States,Netherlands,Netherlands,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Portugal
Call: Academia and industry united innovation and treatment for tuberculosis (UNITE4TB) (H2020-JTI-IMI2-2020-20-two-stage, 2020)
Start date: 2021-06-01
End date: 2028-05-31
Duration (months): 84.0
Total project cost (EUR): 185000000.0
EU funding (EUR): 92500000.0
Participants: 34
Project status: SIGNED

Current anti-tuberculosis (TB) drug regimens face serious limitations at times of increasing antimicrobial drug resistance. Fortunately, for the first time for centuries, several novel anti-TB compounds are available for clinical evaluation. As the traditional approach to testing these in multiple combination regimens is too slow and inefficient new approaches of clinical phase 2 study designs are required if we are to meet the targets of the WHO EndTB strategy to save the lives of millions into the near future. Our consortium brings together a unique group of European and international leaders in TB research and leading industry partners. Together we will provide the necessary comprehensive range of expertise to meet the demands of the UNITE4TB scientific research agenda. Specifically, we will develop a new global standard for phase 2 TB clinical trial designs, utilising simulation tools to identify optimal doses in phase 2A trials and apply a multi-arm multi-stage adaptive randomised controlled 2B/C trial design capable of rapid and simultaneous evaluation of the best candidate regimens. Our innovative phase 2 trials will be performed to the highest regulatory standards, incorporating state-of-the-art microbiology, biomarker investigation and clinical pharmacology. We will take advantage of existing global TB clinical trial networks with the capacity to enrol patients at an unprecedented pace and number across four continents. Artificial intelligence/machine learning technologies will be applied to validate state-of-the art molecular and imaging tools as treatment decision biomarkers with the aim of establishing new, real-time outcome measures. Our consortium will evaluate 3-5 new chemical entities (NCEs) at phase 2A and up to 17 novel combination regimens in phase 2B/C. Our objective is to identify those that have the greatest chance of success in subsequent definitive phase 3 clinical trials and of becoming the global gold-standard TB regimens of the future.

Keywords: innovative clinical trial platform,innovative trial design,artificial intelligence,new chemical entity,drug regimen,microbiology,clinical pharmacology
CODA: Next generation of industrial aerodynamic simulation code (NextSim)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Theme: Public-private partnerships
Destination: European High Performance Computing
Action type: Innovation actions
Partnership: EuroHPC (Art-187)
Countries involved: Spain,Germany,Spain,France,France
Call: Industrial software codes for extreme scale computing environments and applications (H2020-JTI-EuroHPC-2019-1, 2019)
Start date: 2021-03-01
End date: 2024-02-29
Duration (months): 36.0
Total project cost (EUR): 3978096.75
EU funding (EUR): 1884704.63
Participants: 7
Project status: SIGNED

NextSim partners, as fundamental European players in Aeronautics and Simulation, recognise that there is a need to increase the capabilities of current Computational Fluid Dynamics tools for aeronautical design by re-engineering them for extreme-scale parallel computing platforms. The backbone of NextSim is centred on the fact that, today, the capabilities of leading-edge emerging HPC architectures are not fully exploited by industrial simulation tools. Current state-of-the-art industrial solvers do not take sufficient advantage of the immense capabilities of new hardware architectures, such as streaming processors or many-core platforms. A combined research effort focusing on algorithms and HPC is the only way to make possible to develop and advance simulation tools to meet the needs of the European aeronautical industry. NextSim will focus on the development of the numerical flow solver CODA (Finite Volume and high-order discontinuous Galerkin schemes), that will be the new reference solver for aerodynamic applications inside AIRBUS group, having a significant impact in the aeronautical market. To demonstrate NextSim market impact, AIRBUS has defined a series of market relevant problems. The numerical simulation of those problems is still a challenge for the aeronautical industry and their solution, at a required accuracy and an affordable computational costs, is still not possible with the current industrial solvers. Following this idea, three additional working areas are proposed in NextSim: algorithms for numerical efficiency, algorithms for data management and the efficiency implementation of those algorithms in the most advanced HPC platforms. Finally, NextSim will provide access to project results trough the “mini-apps” concept, small pieces of software, seeking synergies with open-source components, which demonstrate the use of the novel mathematical methods and algorithms developed in CODA but that will be freely distributed to the scientific community.

Keywords: aerospace engineering,numerical analysis,simulation,optimization,modelling tools,computational engineering and computer aided design,high performance computing
Integrated inter-sector framework to increase the thermal resilience of European workers in the context of global warming (HEAT-SHIELD)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Preventing disease
Action type: Research and Innovation actions
Countries involved: Italy,Spain,Cyprus,Switzerland,Greece,Slovenia,Sweden,Slovenia,Switzerland,Greece,Netherlands,Netherlands,United Kingdom,United Kingdom,Portugal,United Kingdom,Denmark
Call: Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions (H2020-PHC-2015-two-stage, 2015)
Start date: 2016-01-01
End date: 2021-12-31
Duration (months): 72.0
Total project cost (EUR): 6830936.25
EU funding (EUR): 5777543.25
Participants: 21
Project status: CLOSED

Environmental heating is a growing challenge for our community and problems are already experienced by millions of Europeans during the summertime and aggravated during heat waves or occupational settings. In addition to the well-known health risks related to severe heat stress, a number of studies have confirmed significant loss of productivity due to hyperthermia. Even if countries adopt the EU proposal for limiting global CO2 emissions, climate change and its associated threat to public health will continue for many decades. Thus, it is crucial to develop strategies to mitigate the detrimental health and societal effects of these environmental changes. Stakeholders such as policy makers and the private sector usually lack the technical capabilities or facilities to conduct R&D activities at the level of excellence required for such development. European research institutes have the capacity to conduct the R&D necessary to develop solutions. However, they often lack the capacity to transform these solutions into policies and assess their health, economic and social benefits. The HEAT-SHIELD project will create a sustainable inter-sector framework that will promote health as well as productivity for European citizens in the context of global warming. The project will produce a series of state-of-the-art innovative outcomes including: (i) appropriate technical and biophysical research-based solutions to be implemented when the ambient temperature poses a health threat or impairs productivity (ii) a weather-based warning system with online open access service that anticipates the events that may pose a threat to workers’ health; (iii) scenario-specific policies and solutions aimed at health promotion and preventing loss of productivity (iv) implementation of the formulated policies and evaluation of their health, economic and social benefits. Consequently, the HEAT-SHIELD project provides a multi-sector approach to address the serious environmental challenge.

Keywords: prevention of heat related illness,promotion of productivity,innovation and implementation
SpeecH and Auditory Processing: Effects of Development (SHAPED)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: United Kingdom
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2014, 2014)
Start date: 2015-11-02
End date: 2017-11-01
Duration (months): 24.0
Total project cost (EUR): 183454.8
EU funding (EUR): 183454.8
Participants: 1
Project status: CLOSED

Learning a language involves recognizing the acoustic properties of speech sounds that have a functional role. The abilities of perceiving and processing speech sounds are first constrained by basic hearing abilities. The auditory system extracts and processes the acoustic properties from the input language and thus, fully contributes to the development of phonetic categories. Surprisingly, information concerning the interaction between basic auditory capacities and early development of speech processing is still lacking. The present project seeks to combine two approaches to explore this interaction: developmental psycholinguistics, studying the acquisition of a language, and psychoacoustics, describing the auditory mechanisms linked to the perception of speech sounds. First, this project aims to investigate when and how auditory and speech processes interact. The perception of the speech acoustic information (such as spectro-temporal modulations described by psychoacoustic studies) will be assess in adults and infants from different language environments. Second, this project aims to explore further this interaction by investigating the effect of impaired auditory processes on speech perception development. The perception of speech acoustic information will be assessed in hearing-impaired children having access to the hearing world through hearing aids. This research project highlights an innovative multidisciplinary perspective within the speech perception development field. This project will have significant impacts on 1) general health (i.e., auditory rehabilitation for hearing-impaired children) and 2) language education (i.e., perception of foreign languages during development).

Keywords: speech perception,auditory perception,spectro temporal modulations,infants,children,adults,hearing impairments